Skyrizi meets Phase III endpoints in ulcerative colitis patients

Positive top-line results were achieved from COMMAND, a Phase III maintenance study, showing Skyrizi (risankizumab) 180mg or 360mg subcutaneous [SC]) achieved the primary endpoint of clinical remission (per Adapted Mayo Score) at week 52, as well as key secondary endpoints in adult patients with moderately to severely active ulcerative colitis, said the JAK blocker’s developer, AbbVie (NYSE: ABBV).

In the COMMAND maintenance study, patients from the Phase IIb/III INSPIRE study who responded to induction treatment were re-randomized to receive risankizumab 180mg SC, 360mg SC or withdrawal from risankizumab treatment (risankizumab intravenous [IV] induction-only control group). Around. 75% of patients previously failed at least one advanced therapy (biologics, JAK inhibitors and/or S1P receptor modulators) for ulcerative colitis.1

A significantly higher proportion of patients who received risankizumab 180 mg or 360 mg achieved clinical remission at week 52: 40% and 38%, respectively, compared to 25% in the induction-only control group (p<0.01).